skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

10 Total results for product and free and sample content found

Trialtrove: gold standard clinical trials int...

China trials landscape

18 Oct 2021

Annie Video

本白皮书由Annie Siu博士(PhD,MBA,亚太地区Informa Pharma Intelligence内容总监)与Andrew Benson(MSc,Trialtrove高级总监)撰写,深入剖析中国临床试验的整体格局,介绍临床研究取得的惊人发展。

Topic China

Scrip

Scrip Asia 100 Report Extract

26 Mar 2021

Scrip_Asia_100_Content_Tile

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence

Scrip

Health Sector On High Alert As Wuhan Coronavirus Spreads

By Brian Yang 27 Nov 2020

Health_Sector_On_High_Alert

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

Topic China Infectious Diseases Policy & Regulation Coronavirus

Medtech Insight

Diagnostics Sector On High Alert As Wuhan Coronavirus Spreads

By Brian Yang 27 Nov 2020

Diagnostics_Sector_On_High_Alert

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.

Topic China In Vitro Diagnostics Coronavirus

Pink Sheet

China Regulatory Express Former CFDA Commissioner Bi Makes Comeback

By Brian Yang 27 Nov 2020

CFDA China Forbidden City

Ex-China FDA Commissioner Bi Jingquan’s new role, a waiver of bioequivalence testing for hundreds of drugs, data accuracy requirements and a new crackdown on compliance issues.

Topic China Regulation Compliance

Pink Sheet

China Coronavirus Outbreak Response Critical As First US Case Confirmed

By Brian Yang 27 Nov 2020

China_Coronavirus_Outbreak_Response_Critical

A quickly spreading coronavirus outbreak in China could upend the country’s healthcare priorities as the health regulators and reimbursement agency officials gear up to “control and prevent” the worst public health emergency since the deadly SARS outbreak in 2003.

Topic China Coronavirus Infectious Diseases Policy & Regulation

Scrip

China Coronavirus Cases Up Sharply As Pharma Rushes To Aid

By Brian Yang 27 Nov 2020

China_Coronavirus_Cases_Up_Sharply

AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.

Topic China Coronavirus Policy & Regulation Risk Management

Scrip

Biopharma’s Coronavirus ‘Self-Isolating’: Companies Cancel Investor Meetings, Cut Back Travel

By Kevin Grogan 27 Nov 2020

Corona_Invivo

As the coronavirus spreads beyond China, biopharma companies are taking precautions, with some more wary than others.

Topic China Coronavirus

Pink Sheet

China-US Relationship Hinges On Changing Internal, External Forces

By Brian Yang 18 Nov 2020

US Election China Relations

Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.

Topic US Election 2020 China

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: